Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $980.000M-$995.000M to $1.045B-$1.050B vs $996.102M Est
Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $980.000 million-$995.000 million to $1.045 billion-$1.050 billion vs $996.102 million estimate.
Share
Why It Matters
Kiniksa said it will make more money next year than it predicted before. When a company raises its forecast, it often means things are going better than expected.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.